Ramos, Christian, Efreen Montaño, Alfonso Reyes-López, Fabiola Lemus, Maria Pacheco, Gabriela Hernandez, and Arely Lemus. 2019. “Economic Evaluation of Lenalidomide (Revlimid®) for the Treatment of Mielodysplastic Syndrome With 5q Deletion at low/Intermediate-1 Risk: Evaluación Económica De Lenalidomida (Revlimid®) Para El Tratamiento Del Síndrome Mielodisplásico Con Deleción 5q De Riesgo Bajo/Intermedio-1”. Global and Regional Health Technology Assessment 4 (1):133-40. https://doi.org/10.33393/grhta.2017.387.